Health Care • Medical/Dental Instruments
$3.01 ▼ -0.16
(-5.05%)
MKT CAP: $135.9M • VOL: 2.41M
52W L $1 52W H $3
LUNG // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $90.5M | $83.8M | $68.7M |
| YoY Revenue Growth % | +8.0% | +22.0% | — |
| Gross Profit | $67.1M | $62.0M | — |
| Gross Margin % | 74.2% | 74.0% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$53.7M | -$57.7M | -$61.9M |
| Operating Margin % | -59.3% | -68.9% | -80.0% |
| Net Income (GAAP) | -$54.0M | -$56.4M | -$60.8M |
| EBITDA (Normalized) | -$53.3M | -$56.5M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$32.4M | -$31.5M | -$37.6M |
| Capital Expenditures (CapEx) | $452.0K | $1.4M | — |
| Free Cash Flow (FCF) | -$32.8M | -$33.0M | -$37.6M |
| FCF Margin % | -36.3% | -39.4% | -54.8% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $69.8M | $70.9M | — |
| Total Debt (Short + Long Term) | $37.0M | $34.0M | — |
| Total Stockholders' Equity | $54.1M | $85.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR LUNG.